Chemical Modulation of Mutant mGlu1 Receptors Derived from Deleterious GRM1 Mutations Found in Schizophrenics

详细信息    查看全文

• 作者：Hyekyung P. Cho ; Pedro M. Garcia-Barrantes ; John T. Brogan ; Corey R. Hopkins ; Colleen M. Niswender ; Alice L. Rodriguez ; Daryl F. Venable ; Ryan D. Morrison ; Michael Bubser ; J. Scott Daniels ; Carrie K. Jones ; P. Jeffrey Conn ; Craig W. Lindsley
• 刊名：ACS Chemical Biology
• 出版年：2014
• 出版时间：October 17, 2014
• 年：2014
• 卷：9
• 期：10
• 页码：2334-2346
• 全文大小：764K
• ISSN：1554-8937

文摘

Schizophrenia is a complex and highly heterogeneous psychiatric disorder whose precise etiology remains elusive. While genome-wide association studies (GWAS) have identified risk genes, they have failed to determine if rare coding single nucleotide polymorphisms (nsSNPs) contribute in schizophrenia. Recently, two independent studies identified 12 rare, deleterious nsSNPS in the GRM1 gene, which encodes the metabotropic glutamate receptor subtype 1 (mGlu₁), in schizophrenic patients. Here, we generated stable cell lines expressing the mGlu₁ mutant receptors and assessed their pharmacology. Using both the endogenous agonist glutamate and the synthetic agonist DHPG, we found that several of the mutant mGlu₁ receptors displayed a loss of function that was not due to a loss in plasma membrane expression. Due to a lack of mGlu₁ positive allosteric modulators (PAM) tool compounds active at human mGlu₁, we optimized a known mGlu₄ PAM/mGlu₁ NAM chemotype into a series of potent and selective mGlu₁ PAMs by virtue of a double 鈥渕olecular switch鈥? Employing mGlu₁ PAMs from multiple chemotypes, we demonstrate that the mutant receptors can be potentiated by small molecules and in some cases efficacy restored to that comparable to wild type mGlu₁ receptors, suggesting deficits in patients with schizophrenia due to these mutations may be amenable to intervention with an mGlu₁ PAM. However, in wild type animals, mGlu₁ negative allosteric modulators (NAMs) are efficacious in classic models predictive of antipsychotic activity, whereas we show that mGlu₁ PAMs have no effect to slight potentiation in these models. These data further highlight the heterogeneity of schizophrenia and the critical role of patient selection strategies in psychiatric clinical trials to match genotype with therapeutic mechanism.